MPM Bio IV NVS Strategic Fund
5
24M
3
1
0.40
3
- Stages of investment
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the MPM Bio IV NVS Strategic Fund, startups are often financed by Wellcome Trust, Scottish Widows Investment Partnership, MPM Capital. The meaningful sponsors for the fund in investment in the same round are MPM Capital, BB Biotech Ventures, Wellcome Trust. In the next rounds fund is usually obtained by MPM Capital, BB Biotech Ventures, Wellcome Trust.
The real fund results show that this VC is 5 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year. The top amount of exits for fund were in 2014. This MPM Bio IV NVS Strategic Fund works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2009. The common things for fund are deals in the range of 10 - 50 millions dollars.
Among the various public portfolio startups of the fund, we may underline Proteon Therapeutics, Radius Health Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical, Health Care. The fund has no specific favorite in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 1
- Exits
- 3
- Follow on index
- 0.40
- Investments by industry
- Pharmaceutical (5)
- Biotechnology (5)
- Health Care (4)
- Women's (3)
- Pharmaceuticals (3) Show 4 more
- Investments by region
-
- United States (5)
- Peak activity year
- 2005
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Group Appearance index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Proteon Therapeutics | 28 May 2009 | Biotechnology, Medical, Pharmaceutical | Early Stage Venture | 50M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.